Guidelines on Radioisotope Treatment of Neuroendocrine Tumors

  • Federico Caobelli
  • Laura Evangelista


The present chapter has the aim to provide the current position of radioimmunotherapy (RIT) for the treatment of neuroendocrine tumors (NETs), in the main national and international clinical guidelines. Table 24.1 reported a summary of clinical indications.


  1. 1.
    Öberg K, Knigge U, Kwekkeboom D, Perren A, ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii124–30.PubMedGoogle Scholar
  2. 2.
    Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, North American Neuroendocrine Tumor Society, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42:557–77.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Singh S, Dev C, Kenneche H, Kocha W, Maroun J, Metrakos P, et al. Consensus recommendations for the diagnosis and management of pancreatic neuroendocrine tumors: guidelines from a Canadian National Expert Group. Ann Surg Oncol. 2015;22:2685–99.CrossRefPubMedGoogle Scholar
  5. 5.
    Delle Fave G, O’Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103:119–24.CrossRefPubMedGoogle Scholar
  6. 6.
    Niederle B, Pape U-F, Costa F, Gross D, Kelestimur F, Knigge U, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103:125–38.CrossRefPubMedGoogle Scholar
  7. 7.
    O’Toole D, Kianmanesh R, Caplin M. ENETS consensus guidelines update for management of patients with digestive neuroendocrine tumors: an update. Neuroendocrinology. 2016;103:117–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Dobson R, Vinjamuri S, Hsuan J, Banks M, Terlizzo M, Wieshmann H, et al. Treatment of orbital metastases from a primary midgut neuroendocrine tumor with peptide-receptor radiolabeled therapy using 177 lutetium-DOTATATE. J Clin Oncol. 2013;31:e272–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. NETTER-1 trial investigators. Phase 3 trial of 177lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Clinic of Radiology & Nuclear MedicineBasel University Hospital, University of BaselBaselSwitzerland
  2. 2.Nuclear Medicine and Molecular Imaging UnitVeneto Institute of Oncology IOV – IRCCSPaduaItaly

Personalised recommendations